Arvinas 2025 Q3 Earnings Narrows Net Loss by 28.7% Despite 59.1% Revenue Drop

Arvinas (ARVN) reported fiscal 2025 Q3 results marked by a significant decline in revenue but a notable improvement in net losses. , . , meaning Arvinas outperformed on the bottom line but underperformed on top-line expectations. Management emphasized strategic progress in its pipeline and financial discipline, projecting cash runway through 2028.

Revenue

Arvinas’ total revenue fell sharply to $41.90 million in 2025 Q3, . The decline was attributed to the expiration of a Novartis license agreement and reduced collaboration revenue.

Earnings/Net Income

, . Earnings per share improved to a loss of $0.48 from $0.68, marking the smallest loss in eight years. This reflects cost reductions and operational efficiency gains. Despite the revenue slump, the narrowing loss highlights progress in managing expenses.

Post-Earnings Price Action Review

Following the earnings release, Arvinas’ stock edged up 1.48% on the day but declined 0.21% over the subsequent week. Month-to-date, the stock fell 0.52%, reflecting mixed investor sentiment. While the improved net loss and pipeline advancements drew optimism, the steep revenue decline raised concerns about long-term sustainability.

CEO Commentary

John Houston, Ph.D., highlighted “meaningful pipeline progress,” including Phase 1 data for ARV-102 in Parkinson’s disease and preclinical results for ARV-806 and ARV-027. He emphasized the partnership with Pfizer for ’s commercialization and positioned the quarter as the start of a “data-rich” phase for the company.

Guidance

. Key milestones include a Phase 1b trial for ARV-102 in 2026, FDA approval of vepdegestrant by June 2026, and preclinical data sharing at 2026 medical conferences.

Additional News

Arvinas announced a $100 million share repurchase program, having already bought back 2.56 million shares at $7.91 each. The company also partnered with Pfizer to outlicense vepdegestrant’s commercialization, aiming to secure a launch partner before the June 2026 . Additionally, CEO John Houston underscored strategic growth initiatives, including advancing early-stage programs like ARV-027 for spinal bulbar muscular atrophy.

Polished Article

Arvinas’ Q3 results reflect a challenging revenue environment but improved financial performance. The company’s focus on pipeline advancements and cost management has bolstered investor confidence, though long-term sustainability remains tied to clinical milestones and partnership outcomes. With a robust cash runway and a data-driven roadmap, Arvinas aims to solidify its position in the biotech sector.